psa screening recommendations survey
Recommendations for prostate-specific antigen screening for prostate cancer: A national survey of radiation oncologists and urologists, "Beyond the Abstract," by Simon P. Kim, MD, MPH, et al.
Published on 11 December 2013
BERKELEY, CA (UroToday.com) - Early detection of prostate cancer through the use of prostate-specific antigen (PSA) testing has become an area of significant debate, particularly concerning the benefits and harms of screening men for prostate cancer. Since the introduction of PSA testing, proponents of screening have cited the gradual stage migration to more clinically localized disease and the declines in cancer-specific mortality.[1, 2, 3] Critics of PSA screening often point to the growing concerns of over diagnosis and associated harm to patients from prostate biopsies, as well as negative impactive on treatment-related quality of life.[4, 5, 6]
Against this backdrop, the United States Preventive Services Task Force (USPSTF) recently gave PSA screening a “D” grade, concluding that PSA screening should not be performed among men in the general U.S. population regardless of age. This policy recommendation was based on a systematic review of the 5 clinical trials examining the relative merits of prostate cancer screening in reducing cancer-specific mortality and harm associated with biopsies and primary therapy. In response, the American Urological Association (AUA) and the American Society of Clinical Oncologists recommended a more balanced approach in favor of shared decision-making with patients and physicians -- discussing the benefits and harms due to prostate cancer screening in an effort to make an informed decision, especially in light of the mixed results from the two higher quality clinical trials of prostate cancer screening.[9, 10, 11, 12]
In light of this growing controversy, evaluating the perceptions of PSA screening among radiation oncologists and urologists, who often are involved with the downstream effects of prostate cancer diagnosis and treatment, was needed. In the wake of the preliminary findings from the USPSTF, we performed a national survey of radiation oncologists and urologists about recommendations of PSA screening for men at average risk of prostate cancer, across different age groups.[8, 13] The timing of our study was particularly salient, as it had been more than a decade since a national survey was performed to assess whether radiation oncologists and urologists supported the use of PSA screening. With the discordance between clinical practice guidelines about prostate screening[7, 10, 15, 16, 17] and a recent survey of primary care providers reporting that a majority of primary care providers agreed with the grade D recommendations from the USPSTF,[18, 19] the question about physician support of PSA screening for different age groups bears particular policy relevance for prostate cancer patients, providers, and policymakers.
In this national survey, we found near universal support of PSA testing from radiation oncologists and urologists for men of average risk and aged 50 to 59 (96%) and 60 to 69 (97%) years of age. Conversely, a lower proportion of respondents recommended screening for men aged 75 to 79 (44%) and ≥ 80 (13%) years of age. Another key finding of our study was that urologists were more likely to agree with PSA screening for men 40-49 years old (adjusted odds ratio: 3.1; p < 0.001), but less likely for men 75-79 (adjusted odds ratio: 0.66; p=0.01) and ≥ 80 (adjusted odds ratio: 0.45; p=0.002) years old compared with radiation oncologists. These differences in age-based recommendations for PSA screening may reflect the variations in patient age groups seen in clinical practice, across specialties.
As a consequence, this national survey study concluded that radiation oncologists and urologists continue to see clinical efficacy in recommending PSA-based screening in an age-based targeted approach consistent with existing evidence and clinical practice guidelines. Further research is needed to understand the implications for patients, physicians, and key stakeholders about the effects of the USPSTF and other best practice guidelines on the rates of prostate cancer screening and patient-centered outcomes. However, the downstream consequences of this growing controversy about PSA screening may take years to fully understand. Our results provide context on whether specialists who commonly diagnose and treat prostate cancer patients continue to see value in PSA screening.
- Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Medical Decision Making: An international journal of the Society for Medical Decision Making 2008;28:323-31.
- Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline.Cancer Causes Control 2008;19:175-81.
- Miller DC, Hollenbeck BK. Missing the mark on prostate-specific antigen screening. JAMA 2011;306:2719-20.
- Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9.
- Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.
- Chou R, LeFevre ML. Prostate cancer screening--the evidence, the recommendations, and the clinical implications. JAMA2011;306:2721-2.
- Moyer VA. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;157:120-34.
- Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
- AUA disputes panel's recommendation on prostate cancer screening. American Urological Association, 2012. (Accessed June 1, 2012, at www.auanet.org/content/media/USPSTF_AUA_Response.pdf.)
- Basch E, Oliver TK, Vickers A, et al. Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012.
- Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
- Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
- Kim SP, Karnes RJ, Nguyen PL, et al. A National Survey of Radiation Oncologists and Urologists on Recommendations of Prostate-Specific Antigen Screening for Prostate Cancer. BJU Int 2013.
- Fowler FJ, Jr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000;283:3217-22.
- Brawley OW. Prostate Cancer Screening: What We Know, Don't Know, and Believe. Ann Intern Med 2012.
- Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010;8:240-62.
- Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer: AUA Guideline. J Urol 2013.
- Pollack CE, Noronha G, Green GE, Bhavsar NA, Carter HB. Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med 2012;172:668-70.
- Pollack CE, Platz EA, Bhavsar NA, et al. Primary care providers' perspectives on discontinuing prostate cancer screening.Cancer 2012.
- Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol 2009;181:1622-7; discussion 7.
Nnenaya Q. Agochukwu, MD;a Christopher J. Weight, MD, MS;b Leona C. Han, MBA;c and Simon P. Kim, MD, MPHa as part ofBeyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.
aYale University, Department of Urology, Cancer Outcomes Public Policy and Effectiveness Research Center, New Haven, Connecticut
bUniversity of Minnesota, Department of Urology, Minneapolis, Minnesota
cMayo Clinic, Division of Health Care Policy and Research, Rochester, Minnesota
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 120.7K Cancer specific
- 2.8K Anal Cancer
- 440 Bladder Cancer
- 304 Bone Cancers
- 1.6K Brain Cancer
- 28.4K Breast Cancer
- 388 Childhood Cancers
- 27.8K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.8K Head and Neck Cancer
- 6.3K Kidney Cancer
- 659 Leukemia
- 779 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 232 Multiple Myeloma
- 7.1K Ovarian Cancer
- 47 Pancreatic Cancer
- 485 Peritoneal Cancer
- 5.2K Prostate Cancer
- 1.2K Rare and Other Cancers
- 531 Sarcoma
- 706 Skin Cancer
- 642 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Other Discussion Boards